Volume 70, Issue 5 pp. 740-744
Pediatric and Congenital Heart Disease

Transcatheter closure of high-risk muscular ventricular septal defects with the CardioSEAL occluder: Initial report from the CardioSEAL VSD Registry

D. Scott Lim MD

Corresponding Author

D. Scott Lim MD

Departments of Pediatrics & Medicine, Divisions of Pediatric Cardiology & Cardiovascular Medicine, University of Virginia, Charlottesville, VA

Children's Hospital Heart Center, University of Virginia, Hospital Expansion, 4th Floor, Room 4038, 1215 Lee Street, Charlottesville, VA 22908-0386Search for more papers by this author
Thomas J. Forbes MD

Thomas J. Forbes MD

Department of Pediatrics, Division of Pediatric Cardiology, Wayne State University, Detroit, MI

Search for more papers by this author
Abraham Rothman MD

Abraham Rothman MD

Department of Pediatrics, Division of Pediatric Cardiology, University of Nevada, Las Vegas, NV

Search for more papers by this author
James E. Lock MD

James E. Lock MD

Department of Pediatrics, Harvard University, Boston, MA

Dr. Lock's hospital receives royalties on commercial sales of the CardioSEAL device, and he receives a fraction of those royalties. He has no other conflicts to declare.

Search for more papers by this author
Michael J. Landzberg MD

Michael J. Landzberg MD

Department of Medicine, Harvard University, Boston, MA

Search for more papers by this author
First published: 09 July 2007
Citations: 33

Abstract

Objectives:

The CardioSEAL VSD registry was created to track safety of the device to close high-risk Ventricular Septal Defect (VSD).

Background:

This is the first report from the multi-centered CardioSEAL VSD registry reviewing demographics and initial results.

Methods:

Centers recruited patients with VSD who were high-risk for surgery due to medical condition or anatomic features.

Results:

18 centers contributed data on 55 high-risk patients who had 61 VSD-occlusion procedures, with age of range of 5 days to 65 years and using one to six devices. Implantation approach was transvenous in 48, perventricular in five, and by combined approach in two patients. Ninety-two percent of intended VSD device implants were judged successful. Twenty-two patients had single VSD closed by single device in 18 and by two devices in four patients. All patients <8 kg underwent perventricular device implantation. Thirty-three patients had multiple VSDs which were closed by a single device in 23, and multiple devices in 10. At discharge echocardiography showed total residual flow through all VSDs in which devices were used was classified as “Small” or less in 74%, “More than small” in 11%, and “Uncertain” in 15%. Eight major adverse events occurred in 5/61 cases (8% event rate), with 3/81 devices embolized (4% embolization rate), 5/81 devices surgically explanted (6% explant rate), and no deaths judged to be procedure-related.

Conclusion:

This initial report from the multi-centered CardioSEAL VSD registry demonstrates the safety of the device to close high-risk VSDs. © 2007 Wiley-Liss, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.